drugset / Trial / NCT06299111

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

NCT06299111

Phase 2 Completed 195 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Timeline

Start
2024-09-20
Primary completion
2026-03-27
Completion
2026-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN7508 Monoclonal antibody Intravenous
Subject REGN9933 Monoclonal antibody Intravenous